Andarine (S-4) vs. Enobosarm (Ostarine / MK-2866): A Comparative Review

Abstract

Selective Androgen Receptor Modulators (SARMs) were developed to provide the anabolic benefits of traditional steroids—such as increased muscle mass and bone density—while minimizing androgenic side effects like prostate enlargement and hair loss. Among the most researched SARMs are Andarine (S-4) and Enobosarm (Ostarine/MK-2866). While both compounds belong to the aryl propionamide class, they differ significantly in their clinical progression and safety profiles. Enobosarm has undergone extensive Phase II and Phase III human clinical trials, demonstrating efficacy in treating sarcopenia and cancer cachexia. In contrast, Andarine’s development was largely superseded by newer compounds due to a unique ocular side effect and a shorter half-life, leaving its data primarily rooted in animal models. This article compares the mechanisms, efficacy, and safety profiles of these two compounds based on available scientific literature.

Mechanism Comparison

Both Andarine and Enobosarm are non-steroidal ligands that bind to the androgen receptor (AR) with high affinity. However, their pharmacological behavior in different tissues distinguishes them.

• •Andarine (S-4): S-4 is a partial agonist of the AR. In animal models, it has demonstrated the ability to maintain skeletal muscle mass and bone mineral density while acting as an antagonist or weak agonist in the prostate, thereby reducing the risk of hyperplasia. A unique mechanistic drawback of Andarine is its unintended affinity for the $I_{h}$ channel or similar proteins in the retina, where it can bind to rhodopsin, potentially slowing the recovery of the visual cycle.
• •Enobosarm (Ostarine): Enobosarm acts as a full agonist in anabolic tissues (muscle and bone) and a partial agonist in androgenic tissues. Unlike testosterone, it is not a substrate for 5$\alpha$-reductase (meaning it cannot convert to dihydrotestosterone/DHT) or aromatase (meaning it cannot convert to estrogen). It was specifically designed for improved oral bioavailability and a longer half-life compared to early-generation SARMs like S-4.

Efficacy Comparison

The evidence base for efficacy varies significantly between the two compounds, with Ostarine possessing a much more robust human clinical record.

Andarine (S-4)

Research is primarily restricted to in vivo animal studies. In a landmark study by Kearbey et al. (2007), S-4 was administered to orchidectomized (castrated) rats. The results showed that S-4 was able to restore the weight of the levator ani muscle (a marker for anabolic activity) to levels comparable to intact rats, while maintaining prostate weight at only 16–17% of intact controls. This established S-4 as highly tissue-selective, though human efficacy data remains largely anecdotal or confined to internal pharmaceutical reports not published in peer-reviewed journals.

Enobosarm (Ostarine)

Enobosarm has been validated in multiple human trials. A pivotal Phase II randomized, double-blind, placebo-controlled study by Dalton et al. (2011) evaluated 120 healthy elderly men and postmenopausal women. The study found a dose-dependent increase in lean body mass (LBM), with the 3 mg group gaining an average of 1.3 kg of LBM over 12 weeks. Furthermore, subjects showed significant improvement in physical function, measured by a stair-climb power test.

Safety & Side Effect Comparison

The safety profiles of these two compounds are the primary reason for their differing paths in pharmaceutical development.

| Side Effect | Andarine (S-4) | Enobosarm (Ostarine) | | :--- | :--- | :--- | | Visual Disturbances | Frequent (Yellow tint, night blindness) | Not reported in clinical trials | | HPTA Suppression | Moderate (Dose-dependent) | Mild to Moderate (Dose-dependent) | | Liver Enzymes | Potential elevations (Animal data) | Transient ALT elevations observed | | HDL Cholesterol | Likely reduction | Consistent reduction observed | | Prostate Impact | Minimal (Prostate sparing) | Minimal (Prostate sparing) |

• •Ocular Toxicity: The most distinct side effect of Andarine is "xanthopsia" (yellow-tinted vision) and impaired dark adaptation. This occurs because S-4 molecules bind to the proteins in the retina. This side effect is typically dose-dependent and reversible upon cessation.
• •Lipid and Liver Impact: In human trials of Ostarine, a decrease in HDL (good cholesterol) has been consistently noted. Dobs et al. (2013) reported that while Ostarine was generally well-tolerated in cancer patients, transient elevations in serum alanine aminotransferase (ALT) occurred in some subjects, though these usually returned to normal without stopping the medication.

Pharmacokinetics Comparison

Pharmacokinetics (PK) play a crucial role in the administration of these substances.

• •Half-life:
  • •Andarine has a relatively short half-life, estimated at roughly 3 to 4 hours in animal models, suggesting a need for multiple daily doses to maintain stable blood levels.
  • •Enobosarm has a much longer half-life of approximately 24 hours in humans (Dalton et al., 2011), allowing for once-daily dosing.
• •Bioavailability: Both compounds demonstrate high oral bioavailability, a primary advantage over many traditional anabolic-androgenic steroids (AAS) that require injection or are subject to significant first-pass metabolism.

Research Limitations

The comparison between Andarine and Enobosarm is limited by the "clinical gap."

1. •Human Data Disparity: Enobosarm has been tested in thousands of human subjects across Phase I, II, and III trials. Andarine's clinical development was halted early, meaning there is no long-term peer-reviewed data on its safety or efficacy in humans.
2. •Long-term Effects: Neither compound has been approved by the FDA for human use, and long-term safety data (beyond 6 months to 1 year) is non-existent.
3. •Regulatory Status: Both compounds are currently on the WADA (World Anti-Doping Agency) prohibited list and are not legal for use as dietary supplements.

References

1. •Dalton, J. T., et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle, 2(3), 153-161. doi:10.1007/s13539-011-0034-6.
2. •Dobs, A. S., et al. (2013). Effects of enobosarm on muscle lean body mass and physical function in patients with cancer: a double-blind, randomised, controlled phase 2 trial. The Lancet Oncology, 14(4), 335-345. doi:10.1016/S1470-2045(13)70055-X.
3. •Kearbey, J. D., et al. (2007). Selective Androgen Receptor Modulator (SARM) Treatment Maintains Muscle Mass and Reduces Body Fat in An Orchidectomized Rat Model. Pharmaceutical Research, 24(2), 328-335. doi:10.1007/s11095-006-9152-9.
4. •Gao, W., et al. (2004). Chemistry and Structural Biology of Androgen Receptor. Chemical Reviews, 105(9), 3352-3370. doi:10.1021/cr040633i.
5. •Narayanan, R., et al. (2008). Steroidal and nonsteroidal selective androgen receptor modulators: low therapeutic offerings and high clinical deficit. Nuclear Receptor Signaling, 6, e010. doi:10.1621/nrs.06010.
6. •Zhang, X., et al. (2009). Synthesis and SAR of novel 4-substituted 1,2,3,4-tetrahydroquinoline derivatives as selective androgen receptor modulators. Journal of Medicinal Chemistry, 52(21), 6682–6689. doi:10.1021/jm900854g.